TMER4 i
Alternative Names: TMER4-iLatest Information Update: 06 Jul 2025
At a glance
- Originator Crossignal Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hippo signaling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 May 2025 Preclinical trials in Solid tumours in USA (unspecified route)